Company profile - Brighter Actiste feature image - 16092019 - JPG



SEK598.1m market cap

SEK3.01 last close

Brighter is a Swedish healthtech company addressing common welfare challenges of modern society through a group of innovation companies. Its lead solution, Actiste, currently being commercialised, is aimed at helping people with diabetes adhere to care guidelines and achieve treatment goals.

Investment summary

Brighter is a healthtech company developing solutions for chronic diseases. Its initial strategy is the market introduction of Actiste, a remote monitoring and treatment service for diabetes which recently received two CE marks (Actiste is regulated under both the EU Medical Devices Directive and the In Vitro Diagnostics Directive). The service includes a unique patented device that integrates all the essential features for daily diabetes management, a blood glucose meter, a lancer and an insulin injection pen, into a single unit with built-in mobile connection, and a digital platform for analysing and sharing data with family and friends, healthcare providers and other relevant stakeholders.

Y/E Dec
Revenue (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2018A 1.1 (44.2) (48.8) (74.00) N/A N/A
2019A 3.3 (73.7) (88.7) (105.85) N/A N/A
2020E 24.5 (115.8) (141.4) (71.00) N/A N/A
2021E 133.8 (29.6) (55.2) (27.44) N/A N/A
Industry outlook

In 2017, costs attributed to diagnosed diabetes and associated complications, such as cardiovascular disease and nephropathy, totalled $327bn in the US. Patient opinions of treatment burden are heavily correlated with adherence to self-care.

Last updated on 18/09/2020
Register to receive research on Brighter as it is published
Share price graph
Balance sheet
Forecast net debt (SEKm) 56.1
Forecast gearing ratio (%) 23
Price performance
Actual (12.9) (38.2) (56.0)
Relative* (16.9) (44.8) (62.1)
52-week high/low SEK6.8/SEK2.3
*% relative to local index
Key management
Truls Sjostedt Chairman
Henrik Norström CEO
Anne Zetterberg CFO
Petra Kaur Chief Commercial and Marketing Officer